SJS/TEN are thought to be variants of a single condition. They occur most commonly secondary to medications and as they’re variants of each other, they exist on a spectrum, based on the extent of skin surface area that gets affected.
The unfortunate thing about SJS/TEN is that they occur very unpredictably, and although quite rare they can be severe and sometimes fatal.
The precise underlying mechanism isn’t fully understood, but the basic flow is this – the immune system metabolises a drug, and there is an improper immune reaction to this drug resulting in death of keratinocytes (the major component of the epidermis). This death of keratinocytes causes the epidermis to detach from the underlying skin, resulting in the clinical manifestations of SJS/TEN.
One proposed theory for what causes the keratinocyte death is that there is a T-cell mediated reaction whereby cytotoxic T cells and NK cells result in cell death of keratinocytes via release of granulysin which is a cytolytic protein (we know this as granulysin is found in the blisters of SJS/TEN, and its concentration relates to the severity of the disease).
Another theory is that there is a cell receptor called Fas which, when it binds its ligand (the Fas ligand), it results in cell death of the keratinocyte.
There are also some genes associated with SJS/TEN, so some people can have a genetic predisposition to it.
Drug reactions account for the majority of SJS/TEN reactions (75%), with non-drug reactions thought to account for 25% of the underlying aetiology.
Prodromal Illness: This usually manifests like a flu-like illness:
Acute Illness: The prodrome is followed by acute onset of a painful rash which starts on the trunk. It then extends to affect the face/limbs.
Skin Manifestations
Other Mucosal Involvement
SCORTEN is a severity scoring system for TEN which predicts mortality rates. It can also be used for SJS.
It scales 7 risk factors for high mortality:
A score of 0-1 is associated with a mortality of 3.2%, whilst a score of 5 with a mortality of >90%.
Conservative
Medical
Ciclosporins are sometimes used as some studies report reductions in mortality but this data is still quite limited.
References
https://dermnetnz.org/topics/stevens-johnson-syndrome-toxic-epidermal-necrolysis
https://rarediseases.org/rare-diseases/stevens-johnson-syndrome-and-toxic-epidermal-necrolysis/
https://www.ncbi.nlm.nih.gov/books/NBK459323/
https://dermnetnz.org/cme/emergencies/erythema-multiforme-cme
https://academic.oup.com/milmed/article/185/9-10/e1847/5830797#207542039
https://rarediseases.org/rare-diseases/staphylococcal-scalded-skin-syndrome/
https://empendium.com/mcmtextbook/chapter/B31.II.856.6.